CMS Assessing Vendor Interest In Medicare Competitive Bidding
This article was originally published in The Pink Sheet Daily
Executive Summary
The Centers for Medicare & Medicaid Services’ Request for Information is designed to assess potential vendors’ interest in providing Medicare Part B drugs under a competitive acquisition program. Responses to the RFI are due Jan. 18.
You may also be interested in...
CMS Expects No Significant Change In Average Sales Prices Before 2005
The agency’s final 2005 Physician Fee Schedule includes a second round of preliminary ASPs, with data for a larger number of drugs than in the proposed rule. Final average sales prices for the first quarter of 2005 will be published in December.
Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims
FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.
Efficacy Differences Within Drug Classes Unsupported By Data, FDA's Temple Says
Studies that look for differences in efficacy among members of the same drug class are only performed when necessary for approval, CDER Office of Medical Policy Director Temple tells DIA. While questioning the introduction of "follow-on" compounds, Temple also highlights AstraZeneca's success in achieving a more optimal dose for Nexium.